Head of Regeneron Cell Medicines

Head of Regeneron Cell Medicines

Location:

Cambridge, MA (primary site)

The Head of Regeneron Cell Medicines (RCM) sets the vision, strategy, and execution for Regeneron’s cell medicines portfolio and technology platform. The role spans ex vivo and in vivo CART programs and enabling technologies for delivery, including chemo‑free conditioning. This senior scientific executive oversees cross‑functional initiatives from discovery through early clinical development, builds and mentors high‑performing teams, and partners across the enterprise and with external collaborators to deliver transformative cell‑based therapies.

Strategy and Portfolio Leadership

Define and drive the long‑term scientific vision and portfolio strategy for ex vivo and in vivo cell medicines, aligned to enterprise priorities. Prioritize programs and platform investments using data‑driven governance, scenario planning, and risk/benefit frameworks. Champion innovation in cell engineering, in vivo delivery (e.g., LNPs, viral vectors), and manufacturing to create differentiated therapies.

Scientific Program Oversight

Lead matrixed teams to deliver milestones from target validation to IND, PhaseI manufacturing, and early clinical readouts. Guide technical problem solving across modalities, including CART design, delivery optimization, biodistribution/PK, on/off‑target assessment, and safety risk mitigation. Integrate enabling platforms where justified.

People Leadership and Organizational Development

Build, mentor, and retain a diverse, high‑performing organization of senior scientific leaders and functional experts. Foster a culture of scientific excellence, accountability, collaboration, and inclusion across sites and functions. Implement succession planning, talent development, and performance management.

Cross‑Functional and Cross‑Site Collaboration

Partner closely with Research, Preclinical Development, Clinical, Regulatory, Quality, CMC, Manufacturing, BD, and Finance. Coordinate with vector/delivery, immunology, and translational biomarker teams to accelerate RCM programs to clinical evaluation.

External Innovation and Partnerships

Identify and evaluate external opportunities (academia, biotech, consortia, platforms) to accelerate the pipeline and capabilities. Negotiate and govern collaborations to clear, value‑creating outcomes.

Operational Excellence and Compliance

Own budgets, headcount planning, and resource allocation across programs and platform functions. Ensure adherence to biosafety, ethical guidelines, and regulatory standards (e.g., IND enabling, GxP interfaces). Drive reproducibility, data integrity, and robust decision records.

Executive Communication and Governance

Provide clear, concise updates to executive leadership and governance bodies on strategy, progress, risks, and mitigation plans. Represent Regeneron Cell Medicines at internal and external forums, scientific conferences, and with partners.

Advanced degree (PhD, MD, or MD/PhD) in cell biology, immunology, bioengineering, or a related discipline. 20+years of biopharmaceutical R&D experience with a substantial focus on cell‑based therapies; a proven track record advancing programs from discovery to IND and early clinical trials. Demonstrated leadership of multidisciplinary, multisite teams and senior people leaders in a fast‑paced environment. Deep expertise across key domains: cell engineering (CAR design, viral vectors), potency/identity assays, process and analytical development, and translational biology.

In‑vivo gene delivery experience for CART, including viral and non‑viral modalities (LVV, LNPs), tissue/cell targeting strategies, biodistribution/PK, on/off‑target risk assessment, and immunogenicity management. CMC considerations for in‑vivo modalities versus exvivo products. Familiarity with regulatory pathways for cell and gene therapies (FDA/EMA guidance, IND preparation, RMAT considerations), including in‑vivo gene therapy non‑clinical packages (biodistribution, toxicology, shedding). Strong portfolio management, resource planning, and financial acumen.

Exceptional communication, influence, and stakeholder…